Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

12.23 +0.40 (+3.37%)
Streaming Delayed Price Updated: 10:19 AM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Replimune Group, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful 
From Replimune, Inc.
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Replimune Group Inc. (REPL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
FDA decision expected by August 2, 2026 
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
From Replimune, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune to Present at Two Upcoming Investor Conferences
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
April 10, 2026 Target Action Date for RP1 in Advanced Melanoma 
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure 
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
From Replimune, Inc.
Via GlobeNewswire
News headline image
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Replimune Group, Inc. Investors to Contact the Firm Regarding Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.